Nucleic acids encoding anti-CXCR3 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9765144
SERIAL NO

14480052

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GENZYME CORPORATION450 WATER STREET CAMBRIDGE MA 02141

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Carter, Karen B Fiskdale, US 4 10
Chu, Ruiyin Belle Mead, US 10 45
Connors, Timothy D Shrewsbury, US 17 91
Lodie, Tracey Northbridge, US 7 69
Masterjohn, Elizabeth Hudson, US 4 10
Pinckney, Jason Robert Marlborough, US 5 10
Tedstone, Jennifer Hopkinton, US 4 10
Youd, Michele Lexington, US 9 61

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 19, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 19, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00